{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:10:03Z","timestamp":1791727803453,"version":"4.3.4"},"reference-count":58,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Kids Walk for Kids with Cancer","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"NCI Cancer Center Support Grant","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"Korea Health Technology R&D Project","award":["HI12C1488"],"award-info":[{"award-number":["HI12C1488"]}]},{"name":"Enid A. Haupt Endowed Chair","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100020812","name":"Robert Steel Foundation","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100020812","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Inha University Research Fund"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,3,9]]},"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Success of T cell immunotherapy hinges on the tumor microenvironment (TME), and abnormal tumor vasculature is a hallmark of most solid tumors and associated with immune evasion. The efficacy of T cell engaging bispecific antibody (BsAb) treatment relies on the successful trafficking and cytolytic activity of T cells in solid tumors. Normalization of tumor vasculature using vascular endothelial growth factor (VEGF) blockades could improve efficacy of BsAb-based T cell immunotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Anti-human VEGF (bevacizumab, BVZ) or anti-mouse VEGFR2 antibody (DC101) was used as VEGF blockade, and ex vivo armed T cells (EATs) carrying anti-GD2, anti-HER2, or anti-glypican3 (GPC3) IgG-(L)-scFv platformed BsAb were used. BsAb-driven intratumoral T cell infiltration and in vivo antitumor response were evaluated using cancer cell line-derived xenografts (CDXs) or patient-derived xenografts (PDXs) carried out in BALB-<jats:italic>Rag2<\/jats:italic>\n                     <jats:sup>-\/-<\/jats:sup>IL-2R-<jats:italic>\u03b3c<\/jats:italic>-KO (BRG) mice. VEGF expression on human cancer cell lines was analyzed by flow cytometry, and VEGF levels in mouse serum were measured using VEGF Quantikine ELISA Kit. Tumor infiltrating lymphocytes (TILs) were evaluated using flow cytometry and by bioluminescence; both TILs and tumor vasculature were studied using immunohistochemistry.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>VEGF expression on cancer cell lines increased with seeding density in vitro. BVZ significantly reduced serum VEGF levels in mice. BVZ or DC101 increased high endothelial venules (HEVs) in the TME and substantially enhanced (2.1\u20138.1 fold) BsAb-driven T cell infiltration into neuroblastoma and osteosarcoma xenografts, which was preferential for CD8(+) TILs versus CD4(+) TILs, leading to superior antitumor effects in multiple CDX and PDX tumor models without added toxicities.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>VEGF blockade using specific antibodies against VEGF or VEGFR2 increased HEVs in the TME and cytotoxic CD8(+) TILs, significantly improving the therapeutic efficacy of EAT strategies in preclinical models, supporting the clinical investigation of VEGF blockades to further enhance BsAb-based T cell immunotherapies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2023-006680","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T13:12:01Z","timestamp":1680095521000},"page":"e006680","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":46,"title":["Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3690-6747","authenticated-orcid":false,"given":"Jeong A","family":"Park","sequence":"first","affiliation":[{"name":"Pediatrics, Inha University Hospital, Incheon, Korea (the Republic of)"},{"name":"Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelyn","family":"Espinosa-Cotton","sequence":"additional","affiliation":[{"name":"Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-fen","family":"Guo","sequence":"additional","affiliation":[{"name":"Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Monette","sequence":"additional","affiliation":[{"name":"Laboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Weill Cornell Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6323-5171","authenticated-orcid":false,"given":"Nai-Kong V","family":"Cheung","sequence":"additional","affiliation":[{"name":"Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"key":"2025100311415317000_11.3.e006680.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tig.2008.10.012"},{"key":"2025100311415317000_11.3.e006680.2","doi-asserted-by":"publisher","DOI":"10.1038\/nri2506"},{"key":"2025100311415317000_11.3.e006680.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2444"},{"key":"2025100311415317000_11.3.e006680.4","doi-asserted-by":"crossref","DOI":"10.1038\/s41389-017-0011-9","article-title":"The hypoxic tumour microenvironment","volume":"7","author":"Petrova","year":"2018","journal-title":"Oncogenesis"},{"key":"2025100311415317000_11.3.e006680.5","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1439"},{"key":"2025100311415317000_11.3.e006680.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.10.006"},{"key":"2025100311415317000_11.3.e006680.7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/PPO.0000000000000140","article-title":"Orchestrating the tumor microenvironment to improve survival for patients with pancreatic cancer: normalization, not destruction","volume":"21","author":"Whatcott","year":"2015","journal-title":"Cancer J"},{"key":"2025100311415317000_11.3.e006680.8","doi-asserted-by":"crossref","DOI":"10.1172\/JCI136655","article-title":"The vascular landscape of human cancer","volume":"131","author":"Kahn","year":"2021","journal-title":"J Clin Invest"},{"key":"2025100311415317000_11.3.e006680.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197111182852108"},{"key":"2025100311415317000_11.3.e006680.10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.689132","article-title":"The combination of immune checkpoint blockade and angiogenesis inhibitors in the treatment of advanced non-small cell lung cancer","volume":"12","author":"Ren","year":"2021","journal-title":"Front Immunol"},{"key":"2025100311415317000_11.3.e006680.11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1332"},{"key":"2025100311415317000_11.3.e006680.12","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.pharmthera.2016.06.001","article-title":"Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents","volume":"164","author":"Falcon","year":"2016","journal-title":"Pharmacol Ther"},{"key":"2025100311415317000_11.3.e006680.13","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3627"},{"key":"2025100311415317000_11.3.e006680.14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI65385"},{"key":"2025100311415317000_11.3.e006680.15","doi-asserted-by":"publisher","DOI":"10.1210\/er.2003-0027"},{"key":"2025100311415317000_11.3.e006680.16","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M002016200"},{"key":"2025100311415317000_11.3.e006680.17","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/18.2.363"},{"key":"2025100311415317000_11.3.e006680.18","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.29"},{"key":"2025100311415317000_11.3.e006680.19","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.120.316851"},{"key":"2025100311415317000_11.3.e006680.20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9930"},{"key":"2025100311415317000_11.3.e006680.21","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat Commun"},{"key":"2025100311415317000_11.3.e006680.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"2025100311415317000_11.3.e006680.23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002222","article-title":"Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release","volume":"9","author":"Park","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100311415317000_11.3.e006680.24","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-01012-y","article-title":"Gd2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma","volume":"13","author":"Park","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2025100311415317000_11.3.e006680.25","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0230-T"},{"key":"2025100311415317000_11.3.e006680.26","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1267891","article-title":"Overcoming resistance to HER2-targeted therapy with a novel HER2\/CD3 bispecific antibody","volume":"6","author":"Lopez-Albaitero","year":"2017","journal-title":"Oncoimmunology"},{"key":"2025100311415317000_11.3.e006680.27","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzp077"},{"key":"2025100311415317000_11.3.e006680.28","doi-asserted-by":"publisher","DOI":"10.1016\/0734-9750(92)91451-J"},{"key":"2025100311415317000_11.3.e006680.29","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.07-1175"},{"key":"2025100311415317000_11.3.e006680.30","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0401"},{"key":"2025100311415317000_11.3.e006680.31","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA119.007737"},{"key":"2025100311415317000_11.3.e006680.32","doi-asserted-by":"publisher","DOI":"10.1089\/hgtb.2012.197"},{"key":"2025100311415317000_11.3.e006680.33","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01156-5","article-title":"Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response","volume":"14","author":"Park","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2025100311415317000_11.3.e006680.34","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1008791","article-title":"Understanding high endothelial venules: lessons for cancer immunology","volume":"4","author":"Ager","year":"2015","journal-title":"Oncoimmunology"},{"key":"2025100311415317000_11.3.e006680.35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.736670","article-title":"High endothelial venules: a vascular perspective on tertiary lymphoid structures in cancer","volume":"12","author":"Vella","year":"2021","journal-title":"Front Immunol"},{"key":"2025100311415317000_11.3.e006680.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691"},{"key":"2025100311415317000_11.3.e006680.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0053-3"},{"key":"2025100311415317000_11.3.e006680.38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.081"},{"key":"2025100311415317000_11.3.e006680.39","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M508199200"},{"key":"2025100311415317000_11.3.e006680.40","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.1999.3192"},{"key":"2025100311415317000_11.3.e006680.41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.14.7192"},{"key":"2025100311415317000_11.3.e006680.42","doi-asserted-by":"publisher","DOI":"10.1097\/00005537-200110000-00031"},{"key":"2025100311415317000_11.3.e006680.43","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(95)80023-9"},{"key":"2025100311415317000_11.3.e006680.44","doi-asserted-by":"publisher","DOI":"10.1038\/nri1222"},{"key":"2025100311415317000_11.3.e006680.45","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.21.090501.080131"},{"key":"2025100311415317000_11.3.e006680.46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01687.x"},{"key":"2025100311415317000_11.3.e006680.47","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0431"},{"key":"2025100311415317000_11.3.e006680.48","doi-asserted-by":"publisher","DOI":"10.1038\/nri3298"},{"key":"2025100311415317000_11.3.e006680.49","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10456-021-09792-8","article-title":"High endothelial venules (hevs) in immunity, inflammation and cancer","volume":"24","author":"Blanchard","year":"2021","journal-title":"Angiogenesis"},{"key":"2025100311415317000_11.3.e006680.50","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aak9679","article-title":"Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation","volume":"9","author":"Allen","year":"2017","journal-title":"Sci Transl Med"},{"key":"2025100311415317000_11.3.e006680.51","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ccell.2022.01.002","article-title":"Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy","volume":"40","author":"Asrir","year":"2022","journal-title":"Cancer Cell"},{"key":"2025100311415317000_11.3.e006680.52","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.111.647982"},{"key":"2025100311415317000_11.3.e006680.53","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00978","article-title":"Targeting VEGF\/VEGFR to modulate antitumor immunity","volume":"9","author":"Yang","year":"2018","journal-title":"Front Immunol"},{"key":"2025100311415317000_11.3.e006680.54","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3541"},{"key":"2025100311415317000_11.3.e006680.55","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200939887"},{"key":"2025100311415317000_11.3.e006680.56","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s12307-014-0160-8","article-title":"Immune effects of bevacizumab: killing two birds with one stone","volume":"8","author":"Elamin","year":"2015","journal-title":"Cancer Microenviron"},{"key":"2025100311415317000_11.3.e006680.57","doi-asserted-by":"publisher","DOI":"10.1172\/JCI82585"},{"key":"2025100311415317000_11.3.e006680.58","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.00747","article-title":"Endothelial-to-mesenchymal transition in cancer","volume":"8","author":"Clere","year":"2020","journal-title":"Front Cell Dev Biol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-006680","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T18:42:01Z","timestamp":1759516921000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-006680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":58,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,29]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1136\/jitc-2023-006680"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-006680","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}